Daily Cardiology Research Analysis
Analyzed 222 papers and selected 3 impactful papers.
Summary
Analyzed 222 papers and selected 3 impactful articles.
Selected Articles
1. Recellularized Humanized Bioengineered Biatrial Model for Arrhythmia, Biological Pacemakers, and Optogenetic Studies.
The authors engineered a light-controllable, humanized biatrial tissue by recellularizing decellularized rat atria with human pluripotent stem cell–derived atrial and sinoatrial nodal cells. The construct preserved atrial macro/micro-architecture, exhibited atrial-specific pharmacologic responses, supported biological pacemaking from SAN-like cells at the correct site, and enabled optogenetic control via ChR2/CoChR expression.
Impact: This platform overcomes a key translational gap by providing an anatomically faithful humanized atrial system that supports targeted functional perturbations, including optogenetic pacing. It enables mechanistic studies, disease modeling, and preclinical testing of biological pacemakers.
Clinical Implications: While preclinical, this model can accelerate discovery by enabling precise testing of atrial arrhythmia mechanisms, drug responses, and feasibility/safety of biological pacemaking and optogenetic interventions before animal or human studies.
Key Findings
- Recellularized engineered atria preserved macro- and micro-architecture and displayed atrial-specific identity by markers, optical action potentials, and pharmacologic responses.
- Human PSC–derived sinoatrial nodal cells seeded at the correct anatomical site functioned as a biological pacemaker on optical mapping.
- Optogenetic channels (ChR2 or CoChR) enabled light-controlled pacing and perturbation within the engineered atrial tissue.
Methodological Strengths
- Integration of decellularization/recellularization with hPSC-derived atrial and SAN-like cells preserving anatomical fidelity
- Multimodal validation including immunostaining, optical mapping, pharmacologic testing, and optogenetic control
Limitations
- Use of rat-derived extracellular matrix may not fully recapitulate human atrial biomechanics and signaling
- Lack of in vivo validation and long-term stability/safety assessment of biological pacing
Future Directions: Develop fully human matrices, incorporate patient-specific diseased atrial cells, and evaluate chronic pacing safety/efficacy and drug response reproducibility across platforms.
BACKGROUND: The study of atrial arrhythmias has been hampered by the lack of anatomically relevant human cardiac tissue models and by the inability to perform targeted, functional perturbations in such models. METHODS: To engineer anatomically relevant light-sensitive atrial chambers, we combined human pluripotent stem cells, differentiation protocols yielding atrial and sinoatrial nodal cells, rat heart decellularization/recellularization processes, and optogenetics tools. RESULTS: Immunostaining for chamber-specific cardiomyocyte markers, optical action potential recordings, and the response to atrial-specific pharmacology confirmed the atrial-specific identity of the recellularized engineered tissue. Histological examination verified the preservation of the macroscopic and microscopic atrial architecture of the engineered atria. Optical mapping showed the ability of seeded human pluripotent stem cell-derived sinoatrial nodal cells at the correct anatomic site to serve as a biological pacemaker. Adenoviral transduction and transgenic human pluripotent stem cells were used to express the light-sensitive channels, ChR2 (channelrhodopsin-2) or CoChR ( CONCLUSIONS: A novel, light-controllable, bioengineered humanized biatrial tissue model was established and could be used to model different atrial arrhythmias, for drug testing, for disease modeling, and for evaluation of novel therapeutic interventions such as biological pacemaking and optogenetic interventions.
2. Residual left atrial v wave predicts clinical outcome of transcatheter edge-to-edge mitral valve repair.
In a 299-patient prospective cohort undergoing M-TEER, residual post-implant left atrial v-wave pressure independently predicted 2-year death or HF hospitalization beyond echocardiographic MR grade. A residual v-wave pressure <25 mmHg identified patients with favorable outcomes, offering an actionable intraprocedural target.
Impact: Provides a simple, real-time physiological metric that outperforms imaging alone for prognostication and could directly shape intraprocedural strategy during M-TEER.
Clinical Implications: Targeting a residual LA v-wave pressure <25 mmHg during M-TEER may guide clip optimization or additional grasping and refine procedural endpoints beyond echocardiographic grading.
Key Findings
- Residual LA v-wave pressure decreased from 30.5±15.0 to 23.2±10.4 mmHg after M-TEER (p<0.001).
- Post-implant v-wave pressure independently predicted death or HF hospitalization over 2 years (HR per 10 mmHg 1.29, p=0.012), beyond echo MR grade.
- A residual v-wave pressure <25 mmHg was associated with favorable outcomes even in patients with residual MR grade I–II.
Methodological Strengths
- Prospective observational design with standardized intraprocedural hemodynamic measurements.
- Multivariable analyses demonstrating prognostic value independent of echocardiographic MR grade.
Limitations
- Single physiological center endpoint without randomization may introduce residual confounding.
- Generalizability to different devices or operators not explicitly tested.
Future Directions: Prospective trials testing physiology-guided M-TEER optimization with v-wave targets versus standard echo-guided endpoints, and validation across devices and centers.
AIMS: Intraprocedural assessment of residual mitral regurgitation (MR) is crucial for success of transcatheter edge-to-edge mitral valve repair (M-TEER) yet challenging in the case of ambiguous echocardiographic findings. Monitoring left atrial (LA) pressure can complement evaluation of residual MR after device placement. This study aimed to determine the prognostic impact of intraprocedural changes in LA pressure on the clinical outcome following M-TEER. METHODS: We enrolled 299 patients undergoing M-TEER for primary or secondary MR in a prospective observational study. During the procedure, LA mean (LAmP) and LA v wave pressure (LAvP) were recorded before and after device implantation. The primary endpoint was death or hospitalization for heart failure during a 2-year follow-up. RESULTS: Mean age of the study population was 76.6±8.2 years. Secondary mitral regurgitation was identified in 62.9% of the patients. Reduction to MR grade I or II was achieved in 95.3% of cases. During M-TEER, LAvP decreased from 30.5±15.0 to 23.2±10.4 mmHg (p<0.001) after device implantation, accompanied by a modest reduction of LAmP from 16.6±6.3 to 15.3±5.9 mmHg (p=0.006). LAvP post M-TEER was a strong predictor of death or hospitalization for heart failure in both univariate and multivariate analysis, independent of echocardiographic MR severity (hazard ratio per 10 mmHg 1.37 [1.15-1.63], p<0.001 and 1.29 [1.06-1.57], p=0.012). Residual LAvP below 25 mmHg was strongly associated with favourable outcome irrespective of residual echocardiographic MR grade, including patients with residual MR grade I and II. CONCLUSION: High residual LAvP predicts death or hospitalization for heart failure after M-TEER. LAvP after device implantation provides incremental prognostic information beyond echocardiographic MR grading and may therefore assist intraprocedural decision-making during M-TEER.
3. Robustness of highly purified eicosapentaenoic acid trials and their cardiovascular outcomes.
Across REDUCE-IT, RESPECT-EPA, and JELIS, highly purified EPA added to statins consistently reduced major cardiovascular events, with the strongest robustness in REDUCE-IT. Fragility index analyses highlight how patient phenotype, background therapy, and endpoint design shape apparent effect sizes.
Impact: Clarifies the robustness and context dependence of EPA benefits using fragility metrics, addressing ongoing controversies and informing patient selection.
Clinical Implications: EPA is most reliably beneficial in statin-treated, high-risk patients with elevated triglycerides; fragility analysis should complement conventional statistics when interpreting lipid trial outcomes.
Key Findings
- Three phase 3/4 RCTs (REDUCE-IT, RESPECT-EPA, JELIS) all showed significant primary endpoint reduction with EPA.
- Robustness by fragility index: REDUCE-IT (FI 123) > RESPECT-EPA (FI 49) > JELIS (FI 15).
- Heterogeneity in secondary endpoints tied to population phenotype, background statin therapy, design, and endpoint definitions.
Methodological Strengths
- Focused inclusion of phase 3/4 randomized, placebo-controlled trials.
- Application of fragility index/quotient to complement conventional effect estimates.
Limitations
- Only three trials included; not a pooled meta-analysis of individual patient data.
- Population and endpoint heterogeneity limit cross-trial comparability.
Future Directions: Stratified analyses and IPD meta-analyses to refine phenotypes most likely to benefit; standardized endpoints to reduce heterogeneity in future EPA trials.
AIMS: Despite contemporary statin therapy, patients with atherosclerotic cardiovascular disease or high cardiovascular risk experience a residual risk of major adverse events. Eicosapentaenoic acid (EPA) has been evaluated for additional cardiovascular risk reduction, but the consistency and robustness of trial results remain uncertain. The aim of this study was to assess the robustness of randomized controlled trials (RCTs) of highly purified EPA for cardiovascular outcomes. METHODS: MEDLINE and Scopus were searched for phase 3/4 RCTs of EPA published through June 2025. Eligible studies were randomized and placebo-controlled, and reported dichotomous cardiovascular outcomes. Three trials met the inclusion criteria: REDUCE-IT, RESPECT-EPA, and JELIS. Primary and secondary cardiovascular endpoints were extracted. Conventional effect estimates (hazard ratios, relative risk reduction, number needed to treat) were calculated, and robustness was evaluated using the fragility index and fragility quotient. RESULTS: EPA significantly reduced the primary composite endpoint in REDUCE-IT (17.2 vs. 22.0%; hazard ratio 0.75; fragility index 123, fragility quotient 0.01), RESPECT-EPA (9.1 vs. 12.6%; hazard ratio 0.71; fragility index 49, fragility quotient 0.01), and JELIS (2.8 vs. 3.5%; hazard ratio 0.81; fragility index 15, fragility quotient 0.01). Secondary endpoints showed consistent but heterogeneous reductions in nonfatal myocardial infarction, stroke, and revascularization, with robustness highest in REDUCE-IT and more fragile results in RESPECT-EPA and JELIS. Differences in population phenotypes, background statin therapy, trial design, and endpoint definitions contributed to variability in the effect size and fragility. CONCLUSION: EPA added to statins lowers cardiovascular events, most robustly in high-risk patients with elevated triglycerides. Trial design, endpoints, and patient characteristics drive heterogeneity, while fragility analyses complement conventional metrics in interpreting outcomes.